(NASDAQ: XENE) Xenon Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.8%.
Xenon Pharmaceuticals's revenue in 2026 is $0.On average, 20 Wall Street analysts forecast XENE's revenue for 2026 to be $455,971,399, with the lowest XENE revenue forecast at $0, and the highest XENE revenue forecast at $2,537,470,688. On average, 21 Wall Street analysts forecast XENE's revenue for 2027 to be $6,326,373,585, with the lowest XENE revenue forecast at $1,326,734,674, and the highest XENE revenue forecast at $17,759,394,846.
In 2028, XENE is forecast to generate $26,003,032,950 in revenue, with the lowest revenue forecast at $11,908,229,105 and the highest revenue forecast at $78,560,092,485.